Welcome!

News Feed Item

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

 

PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

 

Summary

 

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

 

For the treatment of CD, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASAs. GlobalData's physician survey showed that these drugs are the mainstay of treatment for mild to moderate CD in India, as well as at earlier lines of therapy for severe disease. While Indian physicians commonly prescribe domestic generics and biosimilars, our primary research revealed that biosimilars were not readily available to those with CD.

 

Scope

 

- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in India from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the India Crohn's disease market.

 

Reasons to buy

 

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

- Make more informed business decisions from insightful and in-depth analysis of drug performance.

- Obtain sales forecast for drugs from 2012-2022 in India.

1 Table of Contents

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 11

3 Disease Overview 12

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 12

3.2 Symptoms 16

3.3 Prognosis 17

3.4 Quality of Life 18

4 Disease Management 19

4.1 Treatment Overview 20

4.2 India 25

4.2.1 Diagnosis 25

4.2.2 Clinical Practice 25

5 Competitive Assessment 27

5.1 Overview 27

5.2 Strategic Competitor Assessment 28

5.3 Product Profiles - Major Brands 29

5.3.1 Remicade (infliximab) 29

5.3.2 Other Marketed Products 35

6 Opportunity and Unmet Need 36

6.1 Overview 36

6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 37

6.3 More Therapies for Anti-TNF-Refractory Patients 38

6.4 Unmet Needs Gap Analysis 39

6.5 Targeted Therapies 40

6.6 Predictive Tools for Early Diagnosis and Treatment 41

7 Pipeline Assessment 42

7.1 Overview 42

7.2 Promising Drugs in Clinical Development 42

7.3 Other Late-Stage Pipeline Products 44

7.3.1 Cx601 44

7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 46

8 Market Outlook 51

8.1 Global Markets 51

8.1.1 Drivers and Barriers - Global Issues 51

9 India 56

9.1 Forecast 56

9.2 Key Events 58

9.3 Drivers and Barriers 59

9.3.1 Driver: Continued investment in the national healthcare system and services 59

9.3.2 Driver: Sizeable CD patient population that will increase over the coming decade 59

9.3.3 Barrier: Loose intellectual property policies present a major challenge for developers with novel drugs 60

9.3.4 Barrier: Limited access to and the high price point of CD therapies, coupled with many Indians' belief in traditional medicine, negatively impacts branded drug sales 60

9.3.5 Barrier: Downward pricing pressure limits drug sales growth 61

10 Appendix 62

10.1 Bibliography 62

10.2 Abbreviations 67

10.3 Methodology 71

10.4 Forecasting Methodology 71

10.4.1 Diagnosed CD Patients 71

10.4.2 Percent Drug-Treated Patients 72

10.4.3 Drugs Included in Each Therapeutic Class 72

10.4.4 General Pricing Assumptions 72

10.4.5 Individual Drug Assumptions 74

10.4.6 Generic Erosion 74

10.5 Physicians and Specialists Included in This Study 75

10.6 Primary Research - Prescriber Survey 76

10.7 About the Authors 77

10.7.1 Author/Reviewer 77

10.7.2 Global Head of Healthcare 77

10.8 About GlobalData 78

10.9 Disclaimer 78

 

1.1 List of Tables

 

Table 1: Symptoms of CD 17

Table 2: Treatment Guidelines for CD 21

Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 23

Table 4: Leading Branded Drugs Used to Treat CD 29

Table 5: Product Profile - Remicade 31

Table 6: Remicade SWOT Analysis, 2013 34

Table 7: Summary of the Minor Therapeutic Classes in CD, 2013 35

Table 8: Overall Unmet Needs in CD - Current Level of Attainment 37

Table 9: Clinical Unmet Needs in CD - Gap Analysis, 2013 40

Table 10: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 42

Table 11: Comparison of Therapeutic Classes in Development for CD, 2013 43

Table 12: Product Profile - Cx601 45

Table 13: Cx601 SWOT Analysis, 2013 46

Table 14: Product Profile - RHB-104 48

Table 15: RHB-104 SWOT Analysis, 2013 50

Table 16: Global CD Market - Drivers and Barriers, 2012-2022 51

Table 17: Sales Forecasts ($) for CD in India, 2012-2022 57

Table 18: Key Events Impacting Sales for CD in India, 2012-2022 58

Table 19: CD Market in India - Drivers and Barriers, 2012-2022 59

Table 20: Physicians Surveyed, By Country 76

 

1.2 List of Figures

 

Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 13

Figure 2: Potential Biologic Drug Targets for CD 16

Figure 3: Patient Care Path for CD 22

Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 43

Figure 5: Sales for CD in India by Drug Class, 2012-2022 58

 

 

To order this report: PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022

http://www.reportlinker.com/p02063644/PharmaPoint-Crohn's-Disease---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
SYS-CON Events announced today that Enzu, a leading provider of cloud hosting solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to foc...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
SYS-CON Events announced today that Stratoscale, the software company developing the next generation data center operating system, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere...
Digital payments using wearable devices such as smart watches, fitness trackers, and payment wristbands are an increasing area of focus for industry participants, and consumer acceptance from early trials and deployments has encouraged some of the biggest names in technology and banking to continue their push to drive growth in this nascent market. Wearable payment systems may utilize near field communication (NFC), radio frequency identification (RFID), or quick response (QR) codes and barcodes...
Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified – now it's a component-based well-performing framework. This immersive one-day workshop at 18th Cloud Expo, led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and the product company SuranceBay, will provide you with everything you wanted to know about Angular 2.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Unless you don’t use the internet, don’t live in California, or haven’t been paying attention to the recent news… you should be aware that self-driving cars are on their way to becoming a reality. I have seen them – they are real. If you believe in the future reality of self-driving cars, then continue reading on. If you don’t believe in the future possibilities, then I am not sure what to do to convince you other than discuss the very real changes that will roll out with the consumer producti...
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
You deployed your app with the Bluemix PaaS and it's gaining some serious traction, so it's time to make some tweaks. Did you design your application in a way that it can scale in the cloud? Were you even thinking about the cloud when you built the app? If not, chances are your app is going to break. Check out this webcast to learn various techniques for designing applications that will scale successfully in Bluemix, for the confidence you need to take your apps to the next level and beyond.